| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/10/2006 | US20060177464 Methods and compositions involving LcrV proteins |
| 08/10/2006 | US20060177463 Fusion polypeptide; includes a first polypeptide that is glycosylated by a alpha 1, 3/4 fucosyltransferase (FUT3), an alpha 1,2 fucosyltransferase (FUT2) and a beta 1,3 galactosyltransferase operably linked to a second polypeptide |
| 08/10/2006 | US20060177462 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 08/10/2006 | US20060177461 Stress proteins and uses therefor |
| 08/10/2006 | US20060177460 Administering to a patient a stress protein joined via a peptide bond to a melanoma antigen to induce or enhanc an immune response against the melanoma antigen |
| 08/10/2006 | US20060177459 Treatment and diagnosis of infertitlity using TGFbeta or activin |
| 08/10/2006 | US20060177458 Compositions of CpG and saponin adjuvants and uses thereof |
| 08/10/2006 | US20060177457 Are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest; for dual phototherapy of tumors and other lesions |
| 08/10/2006 | US20060177456 Apo-2 receptor antibodies |
| 08/10/2006 | US20060177455 Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 08/10/2006 | US20060177454 Method of promoting an immune response with a bispecific antibody |
| 08/10/2006 | US20060177453 Effective in inhibiting tumor cell growth; immunotherapy; purified immunoglobulin; preventing or delaying development of metastasis, treating metastatic cancer, or inhibiting proliferation of metastatic cancer cells |
| 08/10/2006 | US20060177452 EphB receptor-binding peptides |
| 08/10/2006 | US20060177451 Binding molecules for the treatment of myeloid cell malignancies |
| 08/10/2006 | US20060177450 isolated mammalian nucleic acid molecule; antibody; suppressing or modulating metastatic ability of prostate tumor cells, prostate tumor growth or elimination of prostate tumor cells; antitumor agents; gene expression inhbition |
| 08/10/2006 | US20060177449 Antibody and use thereof |
| 08/10/2006 | US20060177448 Inhibiting HER2 shedding with matrix metalloprotease antagonists |
| 08/10/2006 | US20060177447 Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
| 08/10/2006 | US20060177446 Polypeptides that bind an anti-tissue factor antibody and uses thereof |
| 08/10/2006 | US20060177445 Treatment of inflammatory skin diseases |
| 08/10/2006 | US20060177444 Concomitant drug as therapeutic agent for inflammatory bowel disease |
| 08/10/2006 | US20060177443 Integrin antagonists |
| 08/10/2006 | US20060177442 Using cytokine receptor (CD30) specific immunoglobulin to treat hodgkin's disease |
| 08/10/2006 | US20060177441 Agonist antibodies |
| 08/10/2006 | US20060177440 Compositions and methods for detection of antibody binding to cells |
| 08/10/2006 | US20060177439 FcgammaRIIB-specific antibodies and methods of use thereof |
| 08/10/2006 | US20060177438 Methods of altering absorption of hydrophobic compounds |
| 08/10/2006 | US20060177437 Binding peptides: methods for their generation and use |
| 08/10/2006 | US20060177436 Methods for Treating Autoimmune Disorders |
| 08/10/2006 | US20060177435 Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein B ratios |
| 08/10/2006 | US20060177428 Expression vector comprising nucleotide sequences coding endothelial growth factor for use in diagnosis, prevention and treatment of tumor disorders |
| 08/10/2006 | US20060177427 DNA coding for endo-beta-galactosidase |
| 08/10/2006 | US20060177420 treatment of a tumor by administering to a patient an effective amount of active dendritic cells (DC) that are tumor-specific and secrete IL12 |
| 08/10/2006 | DE60024843T2 Impfstoffe zur oralen verwendung die liposomen sowie eine nukleinsäure enthalten Containing vaccines for oral use the liposome and a nucleic acid |
| 08/10/2006 | CA2830588A1 Conjugation of streptococcal capsular saccharides |
| 08/10/2006 | CA2610632A1 Genetically engineered swine influenza virus and uses thereof |
| 08/10/2006 | CA2597198A1 Antibodies that bind to epha2 and methods of use thereof |
| 08/10/2006 | CA2597171A1 Antibodies to oncostatin m receptor |
| 08/10/2006 | CA2597152A1 Use of myostatin (gdf-8) antagonists for treatment of sarcopenia (age-related muscle-wasting) |
| 08/10/2006 | CA2597146A1 Use of myostatin (gdf-8) antagonists for improving wound healing and preventif fibrotic disease |
| 08/10/2006 | CA2597040A1 Hiv tat-cd4 hybrid molecules and methods of use thereof |
| 08/10/2006 | CA2596929A1 T cd4+ epitopes of type i and ii latency antigens of the epstein-barr virus, which can be recognised by the majority of individuals in the caucasian population and applications thereof |
| 08/10/2006 | CA2596802A1 Minor allergen control to increase safety of immunotherapy |
| 08/10/2006 | CA2596731A1 Nucleic acid constructs |
| 08/10/2006 | CA2596730A1 Adjuvanting material comprising pam2cys or pam3cys covalently linked to a metal chelating group |
| 08/10/2006 | CA2596698A1 Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies |
| 08/10/2006 | CA2596697A1 Human antibodies against rabies and uses thereof |
| 08/10/2006 | CA2596683A1 Conjugation of streptococcal capsular saccharides |
| 08/10/2006 | CA2596332A1 Anti-t cell and autoantigen treatment of autoimmune disease |
| 08/10/2006 | CA2596273A1 Adam-9 modulators |
| 08/10/2006 | CA2596115A1 Luca2 and antibodies that bind thereto |
| 08/10/2006 | CA2596075A1 Coated microprojections having reduced variability and method for producing same |
| 08/10/2006 | CA2595976A1 Synergistic combination of xolair/omalizumab/e25 with immunosuppressive agent |
| 08/10/2006 | CA2595906A1 Libraries and methods for isolating antibodies |
| 08/10/2006 | CA2595792A1 Cd20 antibody variants and uses thereof |
| 08/10/2006 | CA2595786A1 Compositions and methods for treating fibrotic disorders |
| 08/10/2006 | CA2595783A1 Vaccine delivery compositions and methods of use |
| 08/10/2006 | CA2595440A1 Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists |
| 08/10/2006 | CA2594636A1 Anti-ephb2 antibodies and methods using same |
| 08/10/2006 | CA2593714A1 Survivin peptide vaccine |
| 08/10/2006 | CA2508532A1 Method for stabilizing dormant organisms by mixing with a moisture free carrier |
| 08/09/2006 | EP1688496A2 Regulation of human P2Y1-like G protein-coupled receptor |
| 08/09/2006 | EP1688488A1 Bispecific antibody substituting for functional proteins |
| 08/09/2006 | EP1688485A1 Culturing circular ssDNA viruses for the production of vaccines |
| 08/09/2006 | EP1688439A1 Fused protein composition |
| 08/09/2006 | EP1688437A1 Antibody composition specifically binding to il-5 receptor |
| 08/09/2006 | EP1688436A1 Composition of antibody capable of specifically binding ccr4 |
| 08/09/2006 | EP1688434A1 Antibody and use of the same |
| 08/09/2006 | EP1688433A1 Antibody composition specifically binding to ganglioside gm2 |
| 08/09/2006 | EP1688432A1 Igm high concentration stabilized solution |
| 08/09/2006 | EP1688430A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 08/09/2006 | EP1688428A1 Method of antigen incorporation into neisseria bacterial outer membrane vesicles and resulting vaccine formulations |
| 08/09/2006 | EP1688415A1 Cytotoxic agents comprising new C-2 modified taxanes |
| 08/09/2006 | EP1687630A2 Diagnostics and therapeutics for diseases associated with aminopeptidase-like 1 (npepl1) |
| 08/09/2006 | EP1687452A2 Human hinge core mimetibodies, compositions, methods and uses |
| 08/09/2006 | EP1687432A2 Compositions and methods for synergistic induction of antitumor immunity |
| 08/09/2006 | EP1687430A1 Immunization against chlamydia infection |
| 08/09/2006 | EP1687427A2 Methods for modulating neuronal responses |
| 08/09/2006 | EP1687423A2 Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases |
| 08/09/2006 | EP1687338A1 Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
| 08/09/2006 | EP1687337A1 A method for the treatment of malignant diseases by inhibiting nucleolin |
| 08/09/2006 | EP1687336A2 Antibodies |
| 08/09/2006 | EP1687335A2 Cancer diagnosis and therapy |
| 08/09/2006 | EP1687334A2 Mucin antigen vaccine |
| 08/09/2006 | EP1687333A2 Method for down-regulation of vegf |
| 08/09/2006 | EP1687332A2 Polynucleotides overexpressed in breast cancer cells , compositions and methods for the therapy and diagnosis of breast cancer |
| 08/09/2006 | EP1687329A2 Optimized expression of hpv 58 l1 in yeast |
| 08/09/2006 | EP1687325A2 Novel sequences encoding hapatitis c virus glycoproteins |
| 08/09/2006 | EP1687322A2 Custom vectors for treating and preventing pancreatic cancer |
| 08/09/2006 | EP1687297A1 Triazine dimers for the treatment of autoimmune diseases |
| 08/09/2006 | EP1687066A2 Methods of modulating immunity |
| 08/09/2006 | EP1687065A2 Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| 08/09/2006 | EP1687033A2 Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines |
| 08/09/2006 | EP1687031A1 Pharmaceutical preparation containing an antibody for the egf receptor |
| 08/09/2006 | EP1687029A1 Neutralizing human antibodies to anthrax toxin generated by recall technology |
| 08/09/2006 | EP1687028A2 Immunoglobulin preparations having increased stability |
| 08/09/2006 | EP1687027A1 Human anti il-15 antibody 146b7 inducing monocytes apoptosis, therapeutical uses thereof |
| 08/09/2006 | EP1687026A1 Method for the treatment of multiple sclerosis by inhibiting il-17 activity |
| 08/09/2006 | EP1687025A1 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system |
| 08/09/2006 | EP1687024A2 Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |